Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Pharmaceutical giants are pivoting toward direct-to-consumer sales and offering steep drug discounts in the United States after President Donald Trump called for lower prescription prices and reduced reliance on “middlemen” such as insurers and pharmacy benefit managers. The move comes ahead of the Trump administration’s planned TrumpRx.gov launch in early 2026 — a federal website that will feature reduced drug prices.
U.S. patients currently pay nearly three times more for medicines than those in other developed countries. Following Trump’s July letters to 17 major firms demanding price cuts, several have responded with new pricing and sales models.
AbbVie announced it will launch its ovarian cancer drug Elahere in the UK at the same U.S. price, aligning with Trump’s “most-favored-nation” pricing policy. AstraZeneca struck a deal with the administration to sell select drugs at steep discounts through Medicaid and TrumpRx.gov, with up to 80% price reductions on some medicines. Bristol-Myers Squibb will cut prices on its blood clot drug Eliquis and plaque psoriasis treatment Sotyktu.
Eli Lilly began shipping high-dose Zepbound directly to consumers, while Novo Nordisk partnered with telehealth providers like GoodRx, Hims & Hers, and Ro to offer Ozempic and Wegovy to cash-paying patients. Pfizer also agreed to lower Medicaid prices to match global rates and will invest $70 billion in U.S. R&D in return for tariff relief.
Sanofi introduced a $35 monthly insulin cap for all U.S. patients, and Roche is exploring direct sales to consumers. Women’s telehealth platform Wisp expanded to offer weight-loss drugs from Eli Lilly and Novo Nordisk with home delivery. Zealand Pharma is also weighing a similar model for its experimental obesity treatment.
Industry group PhRMA plans to launch AmericasMedicines.com in January, helping patients buy directly from manufacturers — signaling a major shift toward affordability and accessibility in the U.S. drug market.
